GENTAK

Post-LOE

gentamicin sulfate

Bristol Myers Squibb

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Oct 2001

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

GENTAK (gentamicin sulfate) by Bristol Myers Squibb is clinical pharmacology gentamicin sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Approved for psoriasis. First approved in 2001.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Gentamicin sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin Sulfate Cream may clear infections that have not responded to treatment with other topical antibiotic agents.…

Indications (1)

psoriasis

Worked on GENTAK at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.